Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Chief Legal Officer | March 08, 2022 | March 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date March 08, 2022 · Filed March 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,659 |
Reported balance
After 2022-03-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-08 · Grant · Acquired 7,875 · Balance 50,659 F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date. F2: Includes 7,875 RSUs. F3: On April 29, 2021, a Form 4 was filed, which inadvertently reported that, following a stock split related to the Issuer's IPO, the Reporting Person directly owned 42,786 shares of Common Stock. Applying the correct stock split ratio, which rounded down fractional shares, the Reporting Person indirectly owned 42,784 shares. This correction has been reflected in this filing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2022-03-08 | Direct | 60,800 |
Reported balance
After 2022-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-08 · Grant · Acquired 60,800 · Balance 60,800 F5: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectPacific Premiere Trust FBO Jaime A. Frias, IRA | 225,549 |
Reported balance
Holding disclosure · report date 2022-03-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 225,549 F4: On April 29, 2021, a Form 4 was filed which inadvertently reported that, following a stock split related to the Issuer's IPO, the Reporting Person indirectly owned 225,551 shares of Common Stock. Applying the correct stock split ratio, which rounded down fractional shares, the Reporting Person indirectly owned 225,549 shares. This correction has been reflected in this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date.
F2: Includes 7,875 RSUs.
F3: On April 29, 2021, a Form 4 was filed, which inadvertently reported that, following a stock split related to the Issuer's IPO, the Reporting Person directly owned 42,786 shares of Common Stock. Applying the correct stock split ratio, which rounded down fractional shares, the Reporting Person indirectly owned 42,784 shares. This correction has been reflected in this filing.
F4: On April 29, 2021, a Form 4 was filed which inadvertently reported that, following a stock split related to the Issuer's IPO, the Reporting Person indirectly owned 225,551 shares of Common Stock. Applying the correct stock split ratio, which rounded down fractional shares, the Reporting Person indirectly owned 225,549 shares. This correction has been reflected in this filing.
F5: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2022 Filed Mar 10, 2022 20:21 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 60,800 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001567619-22-006727 · doc1.xml · derivative · entry 3 Frias Jaime A. · CIK 0001856367 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,800 Underlying: Common Stock · 60,800 shares Expires 2022-03-08 F5 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 20:21 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006727 · doc1.xml · nonDerivative · entry 1 Frias Jaime A. · CIK 0001856367 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,659 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 7,875 RSUs. F3 · balance_after: On April 29, 2021, a Form 4 was filed, which inadvertently reported that, following a stock split related to the Issuer's IPO, the Reporting Person directly owned 42,786 shares of Common Stock. Applying the correct stock split ratio, which rounded down fractional shares, the Reporting Person indirectly owned 42,784 shares. This correction has been reflected in this filing. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionSeries A Preferred Stock · Derivative | 42,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017462 · doc4.xml · derivative · entry 7 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionSeries A Preferred Stock · Derivative | 85,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017462 · doc4.xml · derivative · entry 6 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Pensco Trust Company, LLC Custodian FBO Jaime A. Frias, IRA Disclosed balance after: 0 Underlying: Common Stock · 85,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | OtherSeries A Preferred Stock · Derivative | 988 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017462 · doc4.xml · derivative · entry 5 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,785 Underlying: Common Stock · 988 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F3 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F3 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F3 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | OtherSeries A Preferred Stock · Derivative | 1,976 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017462 · doc4.xml · derivative · entry 4 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Pensco Trust Company, LLC Custodian FBO Jaime A. Frias, IRA Disclosed balance after: 85,570 Underlying: Common Stock · 1,976 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F3 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F3 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. F3 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 329,230 | $17.00 | $5,596,910.00 |
DisclosureSEC source: 0000899243-21-017462 · doc4.xml · nonDerivative · entry 3 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,786 F2 · kind: These shares were sold by the Reporting Person as a selling stockholder in conjuction with the Issuer's Form S-1 filing, Registration Number 333-254863. The offering closed on April 27, 2021. The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters. F2 · price: These shares were sold by the Reporting Person as a selling stockholder in conjuction with the Issuer's Form S-1 filing, Registration Number 333-254863. The offering closed on April 27, 2021. The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionCommon Stock | 42,785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017462 · doc4.xml · nonDerivative · entry 2 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionCommon Stock | 85,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017462 · doc4.xml · nonDerivative · entry 1 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Pensco Trust Company, LLC Custodian FBO Jaime A. Frias, IRA Disclosed balance after: 225,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The Shares had no expiration date. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 20:57 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 93,625 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017028 · doc4.xml · derivative · entry 1 Frias Jaime A. · CIK 0001856367 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,625 Underlying: Common Stock · 93,625 shares Expires 2031-04-22 F1 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on April 22, 2022, with the last installment on April 22, 2025, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.